TABRECTA Royalty Revenues — Total revenues
Incyte TABRECTA Royalty Revenues — Total revenues decreased by 16.3% to $5.98M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.7%, from $6.41M to $5.98M. Over 4 years (FY 2021 to FY 2025), TABRECTA Royalty Revenues — Total revenues shows an upward trend with a 26.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market demand and successful clinical adoption of the therapy, while a decrease may signal increased competition, loss of market share, or changes in the partner's commercial performance.
Detailed definition
This metric represents the total royalty income recognized from the commercialization of a specific oncology therapeutic...
Peer comparison
Comparable to royalty-based revenue streams in pharmaceutical licensing agreements where the company retains intellectual property rights but outsources commercialization to a larger partner.
incy_segment_tabrecta_royalty_revenues_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.48M | $2.75M | $3.12M | $3.48M | $3.58M | $4.11M | $4.23M | $4.18M | $4.80M | $4.14M | $4.68M | $5.23M | $5.30M | $5.93M | $6.29M | $6.41M | $6.63M | $6.51M | $7.14M | $5.98M |
| QoQ Change | — | +10.9% | +13.5% | +11.7% | +2.8% | +14.9% | +2.9% | -1.3% | +14.9% | -13.8% | +13.0% | +11.9% | +1.2% | +11.9% | +6.0% | +2.0% | +3.4% | -1.8% | +9.7% | -16.3% |
| YoY Change | — | — | — | — | +44.6% | +49.8% | +35.7% | +19.9% | +34.0% | +0.6% | +10.5% | +25.3% | +10.4% | +43.2% | +34.4% | +22.5% | +25.2% | +9.9% | +13.6% | -6.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's tabrecta royalty revenues — total revenues?
- Incyte (INCY) reported tabrecta royalty revenues — total revenues of $5.98M in Q1 2026.
- How has Incyte's tabrecta royalty revenues — total revenues changed year-over-year?
- Incyte's tabrecta royalty revenues — total revenues decreased by 6.7% year-over-year, from $6.41M to $5.98M.
- What is the long-term trend for Incyte's tabrecta royalty revenues — total revenues?
- Over 4 years (2021 to 2025), Incyte's tabrecta royalty revenues — total revenues has grown at a 26.6% compound annual growth rate (CAGR), from $10.39M to $26.70M.
- What does tabrecta royalty revenues — total revenues mean?
- The total royalty income earned by the company from a partner's sales of a specific lung cancer drug.